Nemdatine (Memantine Hydrochloride)

Memantine, the active ingredient in Nemdatine, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is prescribed for the treatment of Alzheimer’s disease in adults, helping to reduce excitotoxic neuronal damage. The medication is formulated for once‑daily oral administration and is marketed throughout the European Union.

GNH USA supplies Nemdatine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and is available in multiple packaging options to meet diverse clinical needs.

Nemdatine (memantine) is used in the management of neurodegenerative conditions that involve glutamatergic excitotoxicity, primarily Alzheimer's disease.

- Alzheimer's disease (mild to moderate): improves cognition, memory, and daily functioning. - Alzheimer's disease (moderate to severe): helps maintain functional abilities and may delay progression. - Behavioral symptoms of Alzheimer's disease: may reduce agitation, aggression, and psychosis.

Memantine is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion

Serious or Rare Side Effects: - Hallucinations or visual disturbances - Seizures - Severe allergic reactions such as anaphylaxis

Before initiating therapy, consider the following precautions.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiovascular disease: use caution in patients with hypertension or arrhythmias. - Concomitant NMDA antagonists: avoid combined use to prevent additive neurotoxicity. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from moisture and heat.

Memantine may interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Amantadine: additive CNS effects may increase dizziness and confusion. - Strong NMDA agonists: may reduce memantine efficacy.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may increase plasma concentration of memantine. - Antihypertensives: may enhance hypotensive effect. - Anticholinesterase inhibitors (e.g., donepezil): monitor for increased adverse effects. - CNS depressants (e.g., benzodiazepines): may increase sedation.